MX2022004523A - Formulaciones de liberacion controlada para sustancias fisiologicamente activas altamente lipofilicas. - Google Patents

Formulaciones de liberacion controlada para sustancias fisiologicamente activas altamente lipofilicas.

Info

Publication number
MX2022004523A
MX2022004523A MX2022004523A MX2022004523A MX2022004523A MX 2022004523 A MX2022004523 A MX 2022004523A MX 2022004523 A MX2022004523 A MX 2022004523A MX 2022004523 A MX2022004523 A MX 2022004523A MX 2022004523 A MX2022004523 A MX 2022004523A
Authority
MX
Mexico
Prior art keywords
physiologically active
active substances
controlled release
highly lipophilic
release formulations
Prior art date
Application number
MX2022004523A
Other languages
English (en)
Spanish (es)
Inventor
Annette Grave
Mirko Nowak
Jay Jesko Nowak
Monika Wentzlaff
Sarah Barthold
Christian Geugelin
Original Assignee
Add Advanced Drug Delivery Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Add Advanced Drug Delivery Tech Ltd filed Critical Add Advanced Drug Delivery Tech Ltd
Publication of MX2022004523A publication Critical patent/MX2022004523A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2022004523A 2019-10-16 2020-10-16 Formulaciones de liberacion controlada para sustancias fisiologicamente activas altamente lipofilicas. MX2022004523A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19203580.6A EP3808341A1 (de) 2019-10-16 2019-10-16 Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen
PCT/EP2020/079248 WO2021074403A1 (de) 2019-10-16 2020-10-16 Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen

Publications (1)

Publication Number Publication Date
MX2022004523A true MX2022004523A (es) 2022-09-19

Family

ID=68281185

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004523A MX2022004523A (es) 2019-10-16 2020-10-16 Formulaciones de liberacion controlada para sustancias fisiologicamente activas altamente lipofilicas.

Country Status (10)

Country Link
US (1) US20240139215A1 (enExample)
EP (2) EP3808341A1 (enExample)
JP (2) JP7778069B2 (enExample)
CN (1) CN114945353A (enExample)
AU (1) AU2020365443B2 (enExample)
BR (1) BR112022006643A2 (enExample)
CA (1) CA3157654A1 (enExample)
IL (1) IL292018A (enExample)
MX (1) MX2022004523A (enExample)
WO (1) WO2021074403A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3808336A1 (de) * 2019-10-16 2021-04-21 ADD Advanced Drug Delivery Technologies, Ltd. Kontrolliert freisetzende formulierungen stark lipophiler physiologisch aktiver substanzen
AU2021400338A1 (en) 2020-12-17 2023-07-13 Nalu Bio, Inc. Synthesis of cannabidiol and analogs thereof, and related compounds, formulations, and methods of use
GB2618322A (en) * 2022-04-29 2023-11-08 113 Botanicals Ltd Compositions and methods
US12636296B1 (en) 2025-07-17 2026-05-26 Nalu Bio, Inc. Cannabinol analogs and their use as pharmacologically active agents

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1361864T3 (en) * 2001-02-14 2014-03-03 Gw Pharma Ltd FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids
JPWO2002069957A1 (ja) * 2001-03-01 2004-07-02 グレラン製薬株式会社 フェノフィブラート含有組成物
DE10226494A1 (de) * 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
WO2008024490A2 (en) 2006-08-24 2008-02-28 Theraquest Biosciences, Inc. Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use
US9943491B2 (en) 2013-10-29 2018-04-17 Echo Pharmaceuticals B.V. Compressed tablet containing cannabidiol, method for its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders
WO2015065547A1 (en) * 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
DE102014213548A1 (de) * 2014-07-11 2016-01-14 Hans Brammer Cannabispräparat
JP6581649B2 (ja) * 2014-08-11 2019-09-25 ペロラ ゲーエムベーハーＰｅｒｏｒａ Ｇｍｂｈ 粒子を含む製剤
IL246790A0 (en) * 2016-07-14 2016-09-29 Friedman Doron Self-dissolving compounds of cannabinoids
US20190201350A1 (en) 2016-08-15 2019-07-04 Corr-Jensen Inc. Time release of fat-soluble actives
JP2019137614A (ja) * 2018-02-06 2019-08-22 富士フイルム株式会社 経口用医薬組成物及びその製造方法
DE102019100483A1 (de) * 2019-01-10 2020-07-16 Lts Lohmann Therapie-Systeme Ag Oraler Dünnfilm

Also Published As

Publication number Publication date
IL292018A (en) 2022-06-01
JP7778069B2 (ja) 2025-12-01
WO2021074403A1 (de) 2021-04-22
CA3157654A1 (en) 2021-04-22
CN114945353A (zh) 2022-08-26
AU2020365443A1 (en) 2022-06-02
EP3808341A1 (de) 2021-04-21
EP4045014A1 (de) 2022-08-24
US20240139215A1 (en) 2024-05-02
AU2020365443B2 (en) 2026-06-04
JP2022553653A (ja) 2022-12-26
JP2025182116A (ja) 2025-12-11
BR112022006643A2 (pt) 2022-07-12

Similar Documents

Publication Publication Date Title
BR112022024943A2 (pt) Composição oral efervescente compreendendo um ingrediente ativo
CR9662A (es) Ingrediente farmaceutico canabinoide activo para formas de dosis mejoradas
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
MX2015009772A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
BR112015018087A8 (pt) composto, composição farmacêutica e uso
AR070026A1 (es) Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus
BR112022006643A2 (pt) Formulações de liberação controlada de substâncias fisiologicamente ativas altamente lipofílicas
CL2015002466A1 (es) Formulaciones de compuestos orgánicos
CL2020002101A1 (es) Formulaciones de liberación sostenida de ácido bempedoico.
MX2022006903A (es) Productos orales con irritacion reducida.
CL2022001692A1 (es) Compuestos activos frente a receptores nucleares
MX2020004107A (es) Tabletas de deferiprona de liberacion retrasada y metodos de uso de las mismas.
CO2020005366A2 (es) Composición plaguicida que contiene tidiazurón y ácido poliglutámico
CR20190026A (es) Composición vaginal que comprende una combinación de estrógeno y vitamina d
ECSP10010683A (es) Una formulacion farmacéutica sólida
MX2025011781A (es) Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi
CL2004001843A1 (es) Combinacion de (a) al menos un derivado 2,5-dihidrobencenosulfonico, como el dobeilato calcico, etamsilato y persilato, y (b) al menos un modulador de los canales de potasio, composicion farmaceutica que la contiene y uso como medicamento en profilax
ES3063367T3 (en) Composition having improved voluntary acceptance
MX2017013278A (es) Odorante osmanthus.
ECSP078037A (es) Formulaciones farmacéuticas de liberación inmediata y con una carga de droga elevada de (4-clorofenil)[4-(4-piridilmetil)ftalazin-1-ilo] micronizado, y sus sales
PA8802001A1 (es) Combinación antiretroviral novedosa
MX2022006899A (es) Composicion oral con material de remolacha.
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
AR046213A1 (es) Forma de presentacion del naproxeno sodico
MX2022004522A (es) Formulaciones de liberacion controlada de sustancias fisiologicamente activas altamente lipofilicas.